hydroxyurea has been researched along with Ventricular Dysfunction, Left in 2 studies
Ventricular Dysfunction, Left: A condition in which the LEFT VENTRICLE of the heart was functionally impaired. This condition usually leads to HEART FAILURE; MYOCARDIAL INFARCTION; and other cardiovascular complications. Diagnosis is made by measuring the diminished ejection fraction and a depressed level of motility of the left ventricular wall.
| Excerpt | Relevance | Reference |
|---|---|---|
| " There were no significant differences in adverse events between treatment groups, and no reports of malignant transformation." | 3.01 | Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia. ( Achenbach, H; Egyed, M; Gercheva, L; Gotic, M; Kvasnicka, HM; Warzocha, K; Wu, J, 2021) |
| "Cardiac abnormalities seen in sickle cell anemia (SCA) include diastolic dysfunction, which has been shown to be associated with high morbidity and early mortality." | 1.91 | Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia. ( Hankins, JS; Joshi, V; Kang, G; Martinez, HR; Okhomina, VI; Rai, P, 2023) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rai, P | 1 |
| Okhomina, VI | 1 |
| Kang, G | 1 |
| Martinez, HR | 1 |
| Hankins, JS | 1 |
| Joshi, V | 1 |
| Gotic, M | 1 |
| Egyed, M | 1 |
| Gercheva, L | 1 |
| Warzocha, K | 1 |
| Kvasnicka, HM | 1 |
| Achenbach, H | 1 |
| Wu, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase IIIb, Randomized, Open Label Study to Compare the Safety, Efficacy and Tolerability of Anagrelide Hydrochloride Versus Hydroxyurea in High-Risk Essential Thrombocythaemia Patients.[NCT00202644] | Phase 4 | 150 participants (Actual) | Interventional | 2006-01-13 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Thrombohaemorrhagic events are a well-known complication of the underlying essential thrombocythemia (ET) and disease progression. Events such as arterial and venous thrombosis, serious haemorrhage (including gastrointestinal haemorrhage), and death from vascular causes have been reported in participants who received cytoreductive treatment. (NCT00202644)
Timeframe: From the signing of informed consent until the last study-related visit (Month 36)
| Intervention | participants (Number) |
|---|---|
| Anagrelide | 30 |
| Hydroxyurea | 16 |
A complete response was defined as a platelet count of less than (<) 400x10^9/Liter which was confirmed over 2 consecutive visits at least 28 days apart. (NCT00202644)
Timeframe: Baseline up to Month 36
| Intervention | percenatge of participants (Number) |
|---|---|
| Anagrelide | 58.9 |
| Hydroxyurea | 58.8 |
A partial response is defined as a platelet count of 400-600 x 10^9/Liter and a reduction in platelet count of at least 200 x 10^9/Liter from baseline which was confirmed over 2 consecutive visits at least 28 days apart. (NCT00202644)
Timeframe: Baseline up to Month 36
| Intervention | percentage of participants (Number) |
|---|---|
| Anagrelide | 21.9 |
| Hydroxyurea | 27.9 |
Platelet count was evaluated. (NCT00202644)
Timeframe: Month 6
| Intervention | 10^9 platelets per liter (Mean) |
|---|---|
| Anagrelide | 418.6 |
| Hydroxyurea | 396.0 |
Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a participant did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). (NCT00202644)
Timeframe: Baseline up to Month 36
| Intervention | days (Median) |
|---|---|
| Anagrelide | 177.0 |
| Hydroxyurea | 123.0 |
Time in days from the date of the first dose of study medication to the date of the first visit at which response was classified. If a participant did not achieve response then they were censored at their last visit in the study (Month 36 or withdrawal). (NCT00202644)
Timeframe: Baseline up to Month 36
| Intervention | days (Median) |
|---|---|
| Anagrelide | 61.0 |
| Hydroxyurea | 47.0 |
The LVEF was measured by echocardiography and considered a sufficiently sensitive measure to evaluate any changes in cardiac function. (NCT00202644)
Timeframe: Baseline and Month 1, 2, 3, 6, 9, 12, 18, 24, 30 and 36
| Intervention | percentage of ejection fraction (Mean) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | Change from baseline at Month 1 | Change from baseline at Month 2 | Change from baseline at Month 3 | Change from baseline at Month 6 | Change from baseline at Month 9 | Change from baseline at Month 12 | Change from baseline at Month 18 | Change from baseline at Month 24 | Change from baseline at Month 30 | Change from baseline at Month 36 | |
| Anagrelide | 66.4 | 0.5 | 1.2 | 0.1 | -0.5 | -0.8 | -0.8 | -2.0 | -1.8 | -1.8 | -1.7 |
| Hydroxyurea | 66.9 | -1.1 | 0 | -0.4 | -0.6 | -1.5 | -0.6 | -1.2 | -1.7 | -0.2 | -0.6 |
Platelet count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 3 and 36
| Intervention | 10^9 platelets per liter (Mean) | |
|---|---|---|
| Change from baseline at Month 3 | Change from baseline at Month 36 | |
| Anagrelide | 575.3 | 531.0 |
| Hydroxyurea | 462.2 | 462.8 |
Red blood cell count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 6, 12, 18, 24, 30 and 36
| Intervention | 10^12 cells per liter (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change from baseline at Month 6 | Change from baseline at Month 12 | Change from baseline at Month 18 | Change from baseline at Month 24 | Change from baseline at Month 30 | Change from baseline at Month 36 | |
| Anagrelide | 4.757 | -0.227 | -0.246 | -0.225 | -0.299 | -0.295 | -0.366 |
| Hydroxyurea | 4.787 | -1.467 | -1.398 | -1.323 | -1.281 | -1.339 | -1.362 |
White blood cell count was evaluated throughout the study. (NCT00202644)
Timeframe: Baseline and Month 6, 12, 18, 24, 30 and 36
| Intervention | 10^9 cells per liter (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Baseline | Change from baseline at Month 6 | Change from baseline at Month 12 | Change from baseline at Month 18 | Change from baseline at Month 24 | Change from baseline at Month 30 | Change from baseline at Month 36 | |
| Anagrelide | 9.13 | -0.38 | -1.00 | -1.18 | -1.24 | -1.00 | -1.63 |
| Hydroxyurea | 10.20 | -5.02 | -4.79 | -4.46 | -4.82 | -4.59 | -4.46 |
1 trial available for hydroxyurea and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Cardiovascular Safety of Anagrelide Hydrochloride versus Hydroxyurea in Essential Thrombocythaemia.
Topics: Adolescent; Adult; Aged; Biopsy; Blood Platelets; Bone Marrow Examination; Echocardiography; Europe; | 2021 |
1 other study available for hydroxyurea and Ventricular Dysfunction, Left
| Article | Year |
|---|---|
Longitudinal effect of disease-modifying therapy on left ventricular diastolic function in children with sickle cell anemia.
Topics: Adolescent; Anemia, Sickle Cell; Child; Child, Preschool; Echocardiography; Erythrocyte Transfusion; | 2023 |